GeneDx Shares Plunge 49% Following Earnings Miss and Investigation Launch
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: PRnewswire
- Earnings Miss: GeneDx reported a tenfold increase in net loss for Q1 2026, leading to a 49% drop in share price on May 5, 2025, which wiped out over $900 million in market capitalization, indicating a severe deterioration in the company's financial health.
- Guidance Cut: The company slashed its 2026 revenue guidance by 12% and stated that revenue growth for genome and exome tests would drop to at least 20%, contrasting sharply with previous expectations of 33%-35%, reflecting a pessimistic market outlook on future growth.
- Investigation Launched: Following the stock plunge, Hagens Berman law firm has initiated an investigation into whether GeneDx intentionally or recklessly misled investors, potentially facing legal repercussions, which further exacerbates investor anxiety.
- Severe Market Reaction: The drastic decline in GeneDx's stock price not only undermines investor confidence but may also pose greater challenges for the company in future financing and business expansion, impacting its competitive position in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WGS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WGS
Wall Street analysts forecast WGS stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 53.020
Low
155.00
Averages
171.43
High
200.00
Current: 53.020
Low
155.00
Averages
171.43
High
200.00
About WGS
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GeneDx Shares Plunge 49% Following Earnings Miss and Guidance Cut
- Earnings Disaster: GeneDx reported a tenfold increase in net loss for Q1 2026, causing a 49% drop in share price and erasing over $900 million in market capitalization, severely undermining investor confidence.
- Guidance Downgrade: The company slashed its 2026 revenue guidance by 12%, stating that growth in genome and exome revenue would be at least 20%, significantly lower than previous expectations, indicating a sharp slowdown in business growth.
- Legal Investigation Launched: Following the stock plunge, Hagens Berman law firm has initiated an investigation into whether GeneDx intentionally or recklessly misled investors, potentially facing legal repercussions that could further exacerbate market anxiety.
- Revenue Source Shift: GeneDx's average reimbursement rate (ARR) fell in 2026, primarily due to a significant change in product mix, with genome ARR being only half that of exome, impacting the company's revenue structure and future growth potential.
See More
GeneDx Shares Plunge 49% Following Earnings Miss and Investigation Launch
- Earnings Miss: GeneDx reported a tenfold increase in net loss for Q1 2026, leading to a 49% drop in share price on May 5, 2025, which wiped out over $900 million in market capitalization, indicating a severe deterioration in the company's financial health.
- Guidance Cut: The company slashed its 2026 revenue guidance by 12% and stated that revenue growth for genome and exome tests would drop to at least 20%, contrasting sharply with previous expectations of 33%-35%, reflecting a pessimistic market outlook on future growth.
- Investigation Launched: Following the stock plunge, Hagens Berman law firm has initiated an investigation into whether GeneDx intentionally or recklessly misled investors, potentially facing legal repercussions, which further exacerbates investor anxiety.
- Severe Market Reaction: The drastic decline in GeneDx's stock price not only undermines investor confidence but may also pose greater challenges for the company in future financing and business expansion, impacting its competitive position in the market.
See More
Class Action Lawsuit Filed Against GeneDx Holdings Corp.
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against GeneDx Holdings Corp. aimed at recovering damages for investors who purchased securities between April 16, 2025, and May 4, 2026, highlighting significant transparency issues regarding the company's financial disclosures.
- Allegations Details: The complaint alleges that the company failed to disclose critical information about the importance of Fabric Genomics and its impact on profit margins, which could severely undermine investor confidence and lead to a decline in stock prices.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by August 3, 2026, to participate in potential recovery, demonstrating the legal system's role in protecting investor rights and interests.
- Legal Fee Arrangement: The law firm operates on a contingency fee basis, meaning they will only charge fees if they successfully recover damages, thereby reducing financial risk for investors and encouraging their participation in the lawsuit.
See More
GeneDx Shares Plunge 49% Following Earnings Miss, Investigation Launched
- Dismal Earnings Report: GeneDx's Q1 2026 results revealed a tenfold increase in net loss compared to the previous year, leading to a 12% reduction in full-year revenue guidance, significantly undermining investor confidence in the company's future growth prospects.
- Severe Market Reaction: Following the earnings miss, GeneDx's stock plummeted 49% on May 5, 2025, erasing over $900 million in market capitalization in a single day, reflecting extreme market concerns regarding the company's financial health.
- Investigation Launched: In light of the stock's decline, Hagens Berman law firm has initiated an investigation into whether GeneDx may have violated federal securities laws, urging affected investors to come forward to protect their rights, which could expose the company to legal liabilities.
- Revenue Source Shift: GeneDx's average reimbursement rate was $3,750 in 2025, but a significant adverse change in product mix has led to a drastic downgrade in revenue growth expectations, impacting the company's future profitability and competitive position in the market.
See More
Prosight Management Acquires $42.72 Million Stake in GeneDx Holdings
- Share Acquisition: On May 15, 2026, Prosight Management disclosed the purchase of 468,463 shares of GeneDx Holdings, valued at approximately $42.72 million, indicating confidence in the company despite a 30% decline in its stock price over the past year.
- Asset Value Increase: Following this transaction, the value of GeneDx's position in Prosight increased by $26.46 million to $33.62 million, reflecting the company's potential in the healthcare information services sector, particularly in the application of precision medicine.
- Revenue Growth: GeneDx reported a 17% year-over-year revenue increase to $102.3 million in Q1, with exome and genome testing revenue rising by 27% and testing volume jumping 34%, showcasing strong market demand, although the company lowered its full-year revenue outlook.
- Long-term Investment Potential: Prosight's acquisition suggests confidence in GeneDx's future profitability, especially as precision medicine becomes mainstream, prompting investors to monitor how the company can convert its rapidly growing genomic database into sustainable profitability.
See More
Prosight Acquires $42.72 Million Stake in GeneDx Holdings
- Share Acquisition: On May 15, 2026, Prosight purchased 468,463 shares of GeneDx Holdings, with an estimated transaction value of $42.72 million, reflecting Prosight's confidence in the company's future prospects.
- Increased Holdings Value: Following the transaction, Prosight's total holdings in GeneDx rose to 523,463 shares, valued at $33.62 million, which represents a $26.46 million increase at quarter-end, indicating a positive market response to GeneDx's performance.
- Revenue Growth: GeneDx reported a 17% year-over-year revenue increase to $102.3 million in Q1, with exome and genome testing revenue up 27% and testing volume soaring 34%, highlighting the company's potential in precision medicine.
- Outlook Adjustment: Although GeneDx lowered its full-year revenue guidance to $475 million to $490 million, its ongoing investments in expanding testing access and launching new products demonstrate the company's confidence in future growth opportunities.
See More
GeneDx Shares Plunge 49% Following Earnings Miss and Guidance Cut
- Earnings Disaster: GeneDx reported a tenfold increase in net loss for Q1 2026, causing a 49% drop in share price and erasing over $900 million in market capitalization, severely undermining investor confidence.
- Guidance Downgrade: The company slashed its 2026 revenue guidance by 12%, stating that growth in genome and exome revenue would be at least 20%, significantly lower than previous expectations, indicating a sharp slowdown in business growth.
- Legal Investigation Launched: Following the stock plunge, Hagens Berman law firm has initiated an investigation into whether GeneDx intentionally or recklessly misled investors, potentially facing legal repercussions that could further exacerbate market anxiety.
- Revenue Source Shift: GeneDx's average reimbursement rate (ARR) fell in 2026, primarily due to a significant change in product mix, with genome ARR being only half that of exome, impacting the company's revenue structure and future growth potential.
See More
GeneDx Shares Plunge 49% Following Earnings Miss and Investigation Launch
- Earnings Miss: GeneDx reported a tenfold increase in net loss for Q1 2026, leading to a 49% drop in share price on May 5, 2025, which wiped out over $900 million in market capitalization, indicating a severe deterioration in the company's financial health.
- Guidance Cut: The company slashed its 2026 revenue guidance by 12% and stated that revenue growth for genome and exome tests would drop to at least 20%, contrasting sharply with previous expectations of 33%-35%, reflecting a pessimistic market outlook on future growth.
- Investigation Launched: Following the stock plunge, Hagens Berman law firm has initiated an investigation into whether GeneDx intentionally or recklessly misled investors, potentially facing legal repercussions, which further exacerbates investor anxiety.
- Severe Market Reaction: The drastic decline in GeneDx's stock price not only undermines investor confidence but may also pose greater challenges for the company in future financing and business expansion, impacting its competitive position in the market.
See More
Class Action Lawsuit Filed Against GeneDx Holdings Corp.
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against GeneDx Holdings Corp. aimed at recovering damages for investors who purchased securities between April 16, 2025, and May 4, 2026, highlighting significant transparency issues regarding the company's financial disclosures.
- Allegations Details: The complaint alleges that the company failed to disclose critical information about the importance of Fabric Genomics and its impact on profit margins, which could severely undermine investor confidence and lead to a decline in stock prices.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by August 3, 2026, to participate in potential recovery, demonstrating the legal system's role in protecting investor rights and interests.
- Legal Fee Arrangement: The law firm operates on a contingency fee basis, meaning they will only charge fees if they successfully recover damages, thereby reducing financial risk for investors and encouraging their participation in the lawsuit.
See More
GeneDx Shares Plunge 49% Following Earnings Miss, Investigation Launched
- Dismal Earnings Report: GeneDx's Q1 2026 results revealed a tenfold increase in net loss compared to the previous year, leading to a 12% reduction in full-year revenue guidance, significantly undermining investor confidence in the company's future growth prospects.
- Severe Market Reaction: Following the earnings miss, GeneDx's stock plummeted 49% on May 5, 2025, erasing over $900 million in market capitalization in a single day, reflecting extreme market concerns regarding the company's financial health.
- Investigation Launched: In light of the stock's decline, Hagens Berman law firm has initiated an investigation into whether GeneDx may have violated federal securities laws, urging affected investors to come forward to protect their rights, which could expose the company to legal liabilities.
- Revenue Source Shift: GeneDx's average reimbursement rate was $3,750 in 2025, but a significant adverse change in product mix has led to a drastic downgrade in revenue growth expectations, impacting the company's future profitability and competitive position in the market.
See More
Prosight Management Acquires $42.72 Million Stake in GeneDx Holdings
- Share Acquisition: On May 15, 2026, Prosight Management disclosed the purchase of 468,463 shares of GeneDx Holdings, valued at approximately $42.72 million, indicating confidence in the company despite a 30% decline in its stock price over the past year.
- Asset Value Increase: Following this transaction, the value of GeneDx's position in Prosight increased by $26.46 million to $33.62 million, reflecting the company's potential in the healthcare information services sector, particularly in the application of precision medicine.
- Revenue Growth: GeneDx reported a 17% year-over-year revenue increase to $102.3 million in Q1, with exome and genome testing revenue rising by 27% and testing volume jumping 34%, showcasing strong market demand, although the company lowered its full-year revenue outlook.
- Long-term Investment Potential: Prosight's acquisition suggests confidence in GeneDx's future profitability, especially as precision medicine becomes mainstream, prompting investors to monitor how the company can convert its rapidly growing genomic database into sustainable profitability.
See More
Prosight Acquires $42.72 Million Stake in GeneDx Holdings
- Share Acquisition: On May 15, 2026, Prosight purchased 468,463 shares of GeneDx Holdings, with an estimated transaction value of $42.72 million, reflecting Prosight's confidence in the company's future prospects.
- Increased Holdings Value: Following the transaction, Prosight's total holdings in GeneDx rose to 523,463 shares, valued at $33.62 million, which represents a $26.46 million increase at quarter-end, indicating a positive market response to GeneDx's performance.
- Revenue Growth: GeneDx reported a 17% year-over-year revenue increase to $102.3 million in Q1, with exome and genome testing revenue up 27% and testing volume soaring 34%, highlighting the company's potential in precision medicine.
- Outlook Adjustment: Although GeneDx lowered its full-year revenue guidance to $475 million to $490 million, its ongoing investments in expanding testing access and launching new products demonstrate the company's confidence in future growth opportunities.
See More
